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Abstract
Background: Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrhea in inhabitants from low-income
countries and in visitors to these countries. The impact of the human intestinal microbiota on the initiation and
progression of ETEC diarrhea is not yet well understood.
Results: We used 16S rRNA (ribosomal RNA) gene sequencing to study changes in the fecal microbiota of 12
volunteers during a human challenge study with ETEC (H10407) and subsequent treatment with ciprofloxacin.
Five subjects developed severe diarrhea and seven experienced few or no symptoms. Diarrheal symptoms were
associated with high concentrations of fecal E. coli as measured by quantitative culture, quantitative PCR, and
normalized number of 16S rRNA gene sequences. Large changes in other members of the microbiota varied greatly
from individual to individual, whether or not diarrhea occurred. Nonetheless the variation within an individual was
small compared to variation between individuals. Ciprofloxacin treatment reorganized microbiota populations;
however, the original structure was largely restored at one and three month follow-up visits.
Conclusion: Symptomatic ETEC infections, but not asymptomatic infections, were associated with high fecal
concentrations of E. coli. Both infection and ciprofloxacin treatment caused variable changes in other bacteria that
generally reverted to baseline levels after three months.
Keywords: Diarrhea, Enterotoxigenic Escherichia coli, 16S rRNA gene survey, Microbiota, Antibiotic treatment
Background
Intestinal infection with enterotoxigenic Escherichia coli
(ETEC) has two expected outcomes: watery diarrhea, or
the host remains asymptomatic [1]. The impact of the
human intestinal microbiota on the initiation and pro-
gression of ETEC diarrhea and subsequent antibiotic
treatment is not yet well understood. Although infec-
tions with ETEC are rare in high-income countries, they
are very common in both children and adults in low-
income countries, contributing to an estimated 131,000
deaths per year, as well as being the most common cause
of travelers’ diarrhea with an estimated 10 million cases
per year [2]. The WHO estimated that ETEC alone con-
tributed to over 86 million cases of foodborne illness
and over 26 thousand deaths in 2010 [3]. Because of the
public health burden from ETEC diarrhea, efforts are be-
ing made to develop vaccines to protect against these
pathogens [4]. Candidate vaccines are often evaluated on
volunteer subjects during clinical development. The
ETEC strain used most frequently in volunteer studies is
H10407. About 70 % of naïve volunteers given H10407
following an overnight fast, at a dose of 2x107 colony
forming units (CFU), develop moderate or severe watery
diarrhea [5]. The utility of candidate vaccines can be
assessed by whether immunization reduces the frequency
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and/or severity of diarrhea following the challenge. For
this particular strain, it is important to determine clinical
responses to doses lower than 2x107 CFU, therefore we
used specimens from volunteers given lower doses to ex-
plore questions about changes to the overall gut micro-
biota occurring during an ETEC infection and to address
questions about further changes subsequent to treatment
with ciprofloxacin.
The intestinal microbial community is a complex eco-
system that influences human health in numerous ways:
regulating metabolism and nutrition [6–8], developing
the immune system [9–11], and preventing colonization
and invasion by enteropathogens [12–15]. Dietary habits
[16, 17], natural physiological changes such as pregnancy
[18] or aging [19], infections [20] and medical treat-
ments [21] may alter or disrupt beneficial co-evolved in-
teractions between humans and their microbiota.
Specifically, antibiotic treatments for enteric infections
such as ETEC may cause significant collateral damage to
gut microbiota. The extent of damage is dependent on
the type of antibiotics used and the length of their ad-
ministration [22]. Even a short course of antibiotics may
lead to immediate and drastic shifts in gut microbiota,
resulting in loss of beneficial species, an increase in
drug-resistant strains and predisposition to systematic
infections by pathogens [23–25]. Generally, the intestinal
ecosystem is able to recover from such insults, but re-
covery is often incomplete; long-term observational
studies have shown what appear to be permanent losses
among certain species [21, 24, 26–28]. The vast majority
of these are strict anaerobes important in maintaining a
healthy gut (e.g., by producing short chain fatty acids);
alterations in their abundance in the intestinal microbial
community seem to correlate with the most negative
health effects. Disruption of commensal microbiota may
contribute to a range of significant morbidities such as
antibiotic-associated diarrhea [29], inflammatory bowel
disease [30], irritable bowel syndrome [31], pseudomem-
branous colitis [32], and cancer [33–35].
In this study we followed the changes in the micro-
biota of volunteers during ETEC challenge and subse-
quent treatment with ciprofloxacin.
Methods
Regulatory approval
Use of H10407 was approved under BB-IND#12234.
Study description
We assessed changes in gut microbiota during volunteer
challenge studies to determine the dose response with
ETEC H10407 [5]. The volunteer challenge described here
used doses of 1x105 and 1x106 (ClinicalTrials.gov,
NCT00844493). Each subject received a three-day course
of ciprofloxacin whether or not they exhibited symptoms
and were followed up on days 28 and 84.
Thirty healthy adult participants (8 females and 22
males, average age 33) were challenged with either 1x105
CFU or 1x106 CFU dose of H10407 with bicarbonate
buffer. The health status of subjects was assessed before
challenge (for exclusion criteria, see [5]). Starting on day
5, all subjects received a three-day ciprofloxacin treatment
(500 mg twice daily). Early antibiotic treatment was given
to the patients with severe or moderate diarrhea that
lasted for two days or mild/moderate diarrhea experien-
cing at least two symptoms such as fever (≥38 °C), vomit-
ing, or severe constitutional symptoms (abdominal pain/
cramping, headache, myalgias, nausea). Diarrhea was de-
fined as 1 loose/liquid stool of 300 g or ≥2 loose/liquid
stools totaling ≥200 g during any 48-h period within 120 h
of the challenge. Stool specimens were collected prior to
ETEC infection (day -1, 0) and on the days 1–7, 9, 28, 84
after the infection. We sequenced stool specimens from 5
subjects (54 specimens) who developed moderate to se-
vere diarrhea and 7 subjects (78 specimens) who did not.
The 12 were chosen based on 1a) presence or 1b) the ab-
sence of symptoms and 2) on the maximum number of
stools available. Often our subjects did not have a bowel
movement and no sample was collected.
Challenge strain
H10407 is a wild-type virulent ETEC, serotype O78:H11
that produces both heat-labile and heat-stable toxins and
expresses colonization factor I. In comparison to the
other ETEC strains, H10407 induces a higher proportion
of severe diarrhea, with mild fever and vomiting being
reported in a relatively higher proportion of subjects [5].
Fecal shedding/microbiology
Up to two stool specimens were collected on days 0–4.
Colonization was defined by detecting H10407 in two
stool specimens collected from the same subject at least
24 h after challenge. For quantitative culture, fecal sam-
ples were diluted 10-fold up to 10−5 in phosphate buff-
ered saline pH 7.0; 0.1 ml aliquots were spread onto
MacConkey agar. After overnight incubation, the propor-
tion of 5 E. coli colonies that agglutinated with polyclonal
rabbit anti-H10407 antiserum (International Centre for
Diarrhoeal Disease Research, Bangladesh) was recorded.
Quantities of H10407 were expressed as CFUs per gram
of stool.
DNA isolation and quantitative polymerase chain reaction
DNA was isolated from frozen stools using a bead beater
with 3 mm-diameter solid-glass beads (Sigma-Aldrich,
St. Louis MO, USA) followed by 0.1 mm zirconium
beads (BIO-SPEC Inc., Bartlesville, OK, USA) to disrupt
cells. Cell slurry was centrifuged at 16,000 g for 1 min,
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then the supernatant processed using the Qiagen
QIAamp DNA stool extraction kit (Hilden, Germany).
Extracted DNA was precipitated with ethanol.
Quantitative PCR (qPCR) was performed on 301 sam-
ples using the Applied Biosystems 7500/700 Fast Real-
Time PCR System with software V2.0.5 (ABI, Foster City,
CA, USA) and SYBR Green-Based fluorescent dye, as
described previously [36]. The spectrophotometrically
determined (Nanodrop 1000, ThermoScientific, Waltham,
MA, USA) concentration of H10407 DNA was used to
estimate the number of the heat-labile toxin (LT) copies
per 100 ng of total stool DNA: one nanogram of purified
DNA was estimated to contain 2x105 copies of LT [36].
Amplification and sequencing
Bacterial DNA was amplified using primers targeting the
V1-V2 region of the 16S rRNA gene [20]. Both forward
and reverse primers had a 5’ portion specific for use with
454 GS-FLX Titanium sequencing technology. The for-
ward primers contained a barcode between the Titanium
and gene specific regions, so samples could be pooled to
a multiplex level of 132 samples.
After sequencing, 124 samples passed quality controls,
corresponding to data from 50 samples from 5 volun-
teers with diarrhea and 74 samples from 7 volunteers
without diarrhea. Raw data have been submitted to
NCBI under project ID: PRJNA298336.
Analysis pipeline
Data analysis was performed as in [20]. Sequenced reads
were filtered for quality, first using the default parame-
ters of the 454 software, then by removing reads con-
taining ambiguous characters (N), as well as reads that
were too short (in terms of the number of cycles of the
454 instrument) after trimming. They were then clus-
tered with DNAclust [37] to 99 % identity into clusters
for further annotation using reference data from the
Ribosomal Database Project [38] (rdp.cme.msu.edu, re-
lease 10.4). Sequences without a nearly identical match
to the Ribosomal Database (>100 bp perfect match and >
97 % identity by BLAST) were marked as having “no
genus match” and assigned an operational taxonomic
unit (OTU) identifier. Chimera checking was done with
Perseus/UCHIME [39].
Manual taxonomic classification
Selected OTUs (e.g., OTUs belonging to the pre-
infection biomarker) were aligned using MegaBLAST
against the NCBI nucleotide database. Manual inspec-
tion of the results based on percent identity and query
sequence coverage was used to refine automatically de-
termined taxonomic classifications. If the best BLAST
hit differed by more than 3 % from the query sequence,
or covered less than 95 % of the query sequence, we
restricted classification to the genus level.
Data normalization
We used a Cumulative Sum Scaling (CSS) approach for
normalization, which scales counts by dividing the sum
of each sample’s counts up to and including the pth
quantile (i.e., for all samples j, ⋅ Sp = ∑i(cij|cij ≤ qpj), where
qpj is the p
th quantile of sample j). Normalized counts
are given by cijspj 1000. A complete description is in [40].
Statistical analysis and diversity estimations
To estimate the changes in the abundance of specific
taxa associated with disease, we fit a linear mixed model
for each OTU independently to account for individual
patient variability while controlling for sampling day. We
also included the Cumulative Sum Scaling normalization
factor as a covariate in the linear mixed models. We
retained only OTUs where the boundaries of the esti-
mated Wald-type 95 % confidence intervals agreed in sign
with each other. These analyses were performed with the
R package lme4 version 1.1–8 [41].
To calculate Shannon diversity and Bray-Curtis dissimi-
larity we used the R package Vegan, version 2.3-0 [42].
Analyzing the effect of ciprofloxacin on the gut
microbiota
Samples from 7 patients without diarrhea were ana-
lyzed separately to identify OTUs with the largest
change in abundance immediately after the initiation
of antibiotic treatment. A baseline level of change in
the normalized abundance of OTUs was determined
by comparing OTU abundances between days 4 and 5
(prior to ciprofloxacin treatment), using the formulae:
diff OTUð Þ ¼ abundance OTU ;day5ð Þ−abundance OTU;day4ð Þabundance OTU ;day4ð Þþ1 . The
upper and lower 1 % of the relative difference distribution
were used as cutoffs for identifying significant changes in
OTUs between days 5 and 6 (after ciprofloxacin treat-
ment). The OTUs found to have significantly changed
were aggregated at the species level. For the top 30 species
(15 that increased in abundance and 15 that decreased in
abundance after antibiotic treatment) log-transformed
normalized values were visualized using the R ggplot
package.
Predictive model of diarrheal disease
We developed and trained a model for predicting disease
based on microbiota features. For feature set selection
we only used samples prior to infection. For each log2-
transformed OTU we fit a standard case/control linear
model: yi ¼ bo þ b1  kj þ η log2
nf j
1000þ 1
 
þ ej . Here, yj
is the observed log transformed count, kj is a samples’
Pop et al. BMC Genomics  (2016) 17:440 Page 3 of 11
categorical phenotype (1 if the patient developed diarrhea,
and 0 otherwise), η is an OTU-specific estimate of biases in
PCR amplification that is fit for each OTU independently
as an effect on the samples’ normalization scaling factor, nfj
is the samples’ normalization scaling factor achieved
through CSS [40]. We retained OTUs with an absolute
log2 fold-change greater than 1 for further analysis.
We further reduced the number of OTUs using a lin-
ear kernel support vector machine (SVM). Using solely
features with an absolute weight greater than 0.03 in the
linear kernel (resulting in 32 OTUs) we trained a radial
basis kernel SVM as implemented in R package, kernlab
and caret on samples at time point -1 (prior to infection)
with 10-fold cross validation. We then tested the ability
of the model developed on the pre-infection microbiota
to predict whether post-infection samples belonged to
the patients who developed disease.
Results
Three males and two females had diarrheal symptoms
while four males and three females did not. Subjects
who experienced diarrhea were of similar age (33.2 ±
1.4 years) to those without diarrhea (34.3 ± 2.8 years);
four of five received the higher ETEC dose. Thus, the
symptomatic rates were 27 % for 1x106 CFU and 7 % for
1x105 CFU.
Our sequencing produced 796,915 reads that passed
the quality checks. The reads clustered into 148,147
OTUs, of which only 6,423 were detected in more than
five samples, or were represented by at least 20 se-
quences in a single sample, and were included in further
analysis. After removing low abundance and low preva-
lence OTUs, each of the 124 stool samples we analyzed
comprised at least 605 reads, with an average of 4,657
reads per sample (median 4,349). The number of OTUs
per sample ranged from 58 to 928, with a median of 542
and an average of 522. Each OTU on average contained
90 sequences, ranging from 5, by definition, to 20,996
with a median of 16 sequences.
Overview of microbiota profile
The majority of sequences belonged to the Bacteroidetes
and Firmicutes phyla; lower abundance organisms in-
cluded Proteobacteria, Actinobacteria, Fusobacteria and
Fig. 1 Proportional abundance of the ten most dominant genera in specimens collected from subjects who developed diarrhea (a) and subjects
who did not (b) after challenge with ETEC H10407. Each color represents a different genus. Red marks along the y-axis indicate diarrheal
symptoms. Green dots indicate administration of ciprofloxacin
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Verrucomicrobia. The abundance profile of the top 10
genera is shown in Fig. 1 and in Additional file 1: Figures
S1 and Additional file 2: Figure S2. Further information
about all OTUs is provided in Additional file 3: Table S2
and in .biom format in Additional file 4: File 1.
The number of sequences assigned to the genus
Escherichia varied substantially across time and was
linked to the clinical observations (Fig. 1). Among diar-
rheal specimens, the maximum proportion of the 16S
rRNA gene sequences mapping to Escherichia was 76 %.
Each of the 17 samples containing more than 1 %
Escherichia sequences were collected during diarrheal
episodes or on the days following ciprofloxacin treat-
ment in patients with diarrhea. After three days of cipro-
floxacin treatment, Escherichia could not be detected in
three of the patients who had diarrhea, but was detected
in the other two at 14 % and 9 % of the total bacterial
population.
Assessment of Escherichia abundance by quantitative
culture, quantitative PCR, and 16S rRNA gene sequencing
Quantitative culture and qPCR targeting the heat-labile
toxin (LT) gene were performed using stool specimens
collected between days 0 and 4 of the study, before the
administration of ciprofloxacin (see Additional file 5:
Table S1). Quantitative culture data was available for 44
stools surveyed by 16S rRNA gene sequencing; eight
originated from diarrheal specimens. The presence of
ETEC H10407 was detected by quantitative culture in
eight of eight (100 %) diarrheal stools and thirteen of 36
(36 %) non-diarrheal stools. The maximum abundance
was 3.1x109 CFU per gram of stool. Quantitative PCR
for the LT gene was available for 46 samples, 9 of which
originated from diarrheal samples. The challenge strain
was detected by qPCR in all diarrheal stools and in 21 of
37 (57 %) non-diarrheal stools. Thirteen samples (9
symptomatic and 4 asymptomatic) exceeded the 1.4x104
copies of the LT gene threshold, proposed by Lindsay et
al. [36].
The proportional abundance of Escherichia estimated
through 16S rRNA gene sequencing correlated with the
abundance estimated by culture and qPCR. The propor-
tional abundance of 16S rRNA gene reads from Escheri-
chia OTUs ranged from 0 to 76 %. In diarrheal samples,
the correlation between 16S rRNA gene counts of Escheri-
chia and quantitative culture was adjusted R2 = 0.89, p =
0.0002 and for qPCR, was adjusted R2 = 0.66, p = 0.005,
suggesting the OTUs identified in these samples corre-
sponded to the challenge strain (Fig. 2). In non-diarrheal
samples, the 16S rRNA gene counts were not correlated
with either measure. The limit of detection of the 16S
rRNA gene survey assay was estimated to be 107 CFU/g of
stool for an average sequencing depth of 6,000 reads.
Inter-patient Bray Curtis distances were significantly
larger than intra-patient distances
The inter-personal variability in the distal gut microbiota
exceeded the effect of perturbations (Fig. 3), as evi-
denced by smaller distances found between the micro-
biota of samples from the same patient versus samples
Fig. 2 Spearman correlation between 16S rRNA normalized gene count abundances assigned to Escherichia (x-axis) and either (a) qPCR LT or (b)
quantitative culture. All axes are on log10 scale. The size of each of the circles is proportional to the total number of reads in the sample. Orange
and green circles represent diarrheal and non-diarrheal samples, respectively. Orange lines are the linear correlation in stools from patients with
diarrhea. Correlation between 16S rRNA gene counts of Escherichia and quantitative culture estimates and correlation between 16S rRNA gene
counts and qPCR LT estimates are high in diarrheal samples, when E. coli is abundant. In non-diarrheal samples, the correlation is low
Pop et al. BMC Genomics  (2016) 17:440 Page 5 of 11
compared across different patients (Bray Curtis distance,
p = 8x10−26). Diarrheal episodes generally did not induce
large shifts (labeled points in Fig. 3a). In contrast, in certain
patients antibiotic treatment by itself or combined with
disease induced large shifts in the microbiota, but this was
not consistent, and even the highly perturbed microbiota
profiles tended to return to close to the pre-treatment state
at 28 and 84 day follow-ups (arrows Fig. 3b).
Changes in microbial diversity during the challenge study
and subsequent ciprofloxacin treatment
The diversity of the stool microbiota (Fig. 4), as measured
by the Shannon diversity index, was highly variable across
all individuals. Both diarrhea [20] and ciprofloxacin treat-
ment [21, 24] led to significant decreases in overall diver-
sity (p < 0.05, rank-sum Wilcoxon test) but neither the
onset of symptoms nor administration of antibiotics pro-
duced the same consequences in all individuals. Overall
diversity of the gut microbiota was largely restored in all
patients by follow-up visits at days 28 and 84. Ciprofloxa-
cin treatment appeared to have a more severe impact on
overall diversity than diarrheal disease. Excluding Escheri-
chia, six of the top seven most frequently occurring
genera (Bacteroides, Streptococcus, Prevotella, Dialister,
Akkermansia, Blautia) had changes of over 30 % of nor-
malized sequences in different individuals (see Additional
file 1: Figures S1 and Additional file 2: Figure S2), most of
these extreme changes occurred after the administration
of the antibiotic (10 increases pre and 23 increases post
initial antibiotic, binomial p = 0.016). However the effects
of diarrhea and ciprofloxacin cannot be easily disentangled
given that patients were treated after they developed se-
vere diarrheal symptoms. All five cases and five of seven
controls exhibited large fluctuations in abundance within
individual genera.
Fine-level reorganization of specific taxonomic groups
upon ciprofloxacin treatment
Our OTU-level analysis of changes in the microbiota after
ciprofloxacin treatment revealed a striking reorganization
of certain taxonomic groups. Some taxa were detected be-
fore and after but not during ciprofloxacin treatment,
while other taxa were detected only during ciprofloxacin
treatment. Figure 5 shows sets of OTUs from one individ-
ual (results from other controls are shown in Additional
file 6: Figure S3). The first panel (largely clustered towards
the top of the figure) are OTUs present in the pre-
infection (days -1, 0) and pre-treatment (days 1–5) micro-
biota but which disappear below the level of detection
upon antibiotic treatment, then reemerge at days 28 and
84. A second group of OTUs (bottom of the figure) is
most abundant after antibiotic treatment.
Specific taxonomic changes associated with diarrheal
disease
Patients who eventually developed diarrheal disease had a
higher proportional abundance of OTUs from the genus
Escherichia as well as Bacteroides dorei, Bacteroides
Fig. 3 Samples cluster by patient not phenotype in PCoA plots. a Samples pre-ciprofloxacin treatment. All data points are shown, with black
squares highlighting samples obtained during diarrheal episodes. b Samples after antibiotic treatment. Pre-treatment samples summarized as
95 % confidence ellipses (ordiellipse function from the R vegan package). Post-treatment samples shown as points with symbols indicating
whether they were derived immediately post-antibiotic treatment, or at 1 and 3 month follow ups. Shifts introduced by antibiotic treatment,
and transition to post study microbiota highlighted for selected patients with colored arrows
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ovatus, and Barnesiella intestinihominis. In contrast, the
microbiota of controls were enriched in OTUs from the
species Bacteroides vulgatus, Bacteroides xylanisolvens,
and Parabacteroides distasonis. By restricting our analysis
to just the time-points prior to the development of dis-
ease, Bacteroides dorei and to a lesser extent Barnesiella
intestinihominis remained associated with the cases, while
in controls only Bacteroides vulgatus remained signifi-
cantly enriched. See Additional file 3: Tables S2 and Add-
itional file 7: Table S3 for full details.
The pre-infection microbiota – a predictor of disease
onset?
To further explore whether pre-disease microbiota could
be predictive of the eventual outcomes, we identified a
'biomarker' comprising 32 bacterial OTUs (See Fig. 6). A
radial basis kernel SVM model with an AUROC of 0.83
based on this biomarker achieved 76 % accuracy in pre-
dicting whether a sample originated from a patient who
eventually developed diarrhea. The most robust predictors
of disease development (as judged by a visual inspection
of their prevalence and abundance in the pre-infection
microbiota) included Bacteroides dorei, Prevotella sp.,
Alistipes onderdonkii, Bacteroides sp. (ovatus), and Blautia
sp., while the predictors of resistance against diarrheal dis-
ease included Sutterella sp., Prevotella copri, and Bacter-
oides vulgatus. Full information is provided in Additional
file 8: Table S4.
Discussion
Challenging the intestinal microbiota with ETEC has
two expected outcomes: either invasion is successful,
resulting in colonization and induction of disease, or the
invaders are repelled, and the health of the human host
is maintained. Our study focused on changes in micro-
biota during an ETEC challenge. Despite the small sample
size and the large variations among individuals, novel
trends emerge that may lead to firmer conclusions. We
demonstrated that the proportional abundance of 9 to
76 % E. coli 16S rRNA gene sequences in diarrheal sam-
ples was associated with successful invasion by ETEC,
confirmed by both quantitative culture and qPCR.
a b
Fig. 4 Shannon measure of observed bacterial diversity across time for each of the individuals with diarrheal episodes (a) and without (b). Red
circles indicate diarrheal episodes. Green circles indicate antibiotic treatment
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There is growing interest in bolstering resistance to in-
fections by altering the microbiota. Previous studies have
attempted to correlate microbiota patterns with preven-
tion or development of gastrointestinal pathogens such
as Shigella [43], Clostridium difficile [44] and vanco-
mycin resistant enterococci [45], and have identified
candidate species that could be used to enhance defense
against these pathogens [44, 46]. Similarly, our study re-
vealed associations between the pre-challenge micro-
biota and the risk of symptoms following challenge with
ETEC. Our biomarker of 32 OTUs predicted with rea-
sonable accuracy whether an individual would develop
diarrhea or not. This observation warrants further study,
since the 12 OTUs that were associated with not devel-
oping diarrheal disease may be taxa that prevent the
growth of ETEC; if so, these might have potential thera-
peutic uses as novel probiotics. Although little is cur-
rently known about the impact of our candidate taxa on
pathogenic microbes, Prevotella copri was recently anti-
correlated with diarrheal disease in infant cohorts from
Fig. 5 Shift of microbial community structure after ciprofloxacin treatment (administered on days 5, 6, 7 [labels on the x-axis]) for subject P03.
Several OTUs, primarily Prevotella and Faecalibacterium, decreased below the limit of detection after antibiotic treatment but regained their
abundance by the 1 month follow-up. The scale is the log of the normalized abundance
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low income countries [20] and Bacteroides spp. have
been linked to resolution of C. difficile diarrheal disease
following fecal microbiota transplant [47].
After the ETEC challenge, the patients were treated
with ciprofloxacin. After treatment, antibiotic resistant
strains, which may already be present at low abundance
under normal conditions, replace the susceptible organ-
isms killed by the drug. However, the sensitive strains
may not be entirely eradicated, allowing their numbers
to recover post-treatment. Such dynamics were apparent
in some of the samples. Co-existence of sensitive and re-
sistant strains in the same sample in the face of opposite
primary selective pressure has potential implications for
understanding ecological balance and treatments for
disease. It may be that rare forms (species, taxa) have
a selective advantage simply because they are rare
(frequency-dependent selection) even in the face of
strong directional selection such as that imposed by
antibiotics.
Our results confirm those of Dethlefsen et al. [21] and
others: inter-individual variation is greater than intra-
individual variation following ciprofloxacin treatment,
and the microbiota tends to recover within a few weeks.
Impact on the gut microbiota depends on the duration
of the course and degree of resistance in the community,
consistent with a previous observation that the structure
of the gut microbiota is determined by long-term dietary
habits and is less affected by short term perturbations [17].
These observations suggest that short-term, single-course
use of ciprofloxacin for infections is unlikely to result in
long-term and large-scale microbiota perturbations.
Conclusions
One of the clearest conclusions from our study is that,
despite the major measurable perturbations, each indi-
vidual’s microbiota maintained its overall uniqueness
and its general community structure. As such, our study
leads to hypotheses about the microbiota rather than
firm conclusions. Nonetheless, we believe the relatively
large amount of variation between the microbiota of indi-
viduals should be seen as an asset rather than a limitation.
Keystone species, and critical interactions between com-
munity members, can only be teased out from possible
confounding factors if there are sufficient inter-personal
differences between microbiota communities. Our study,
therefore, provides a first indication of the microbial taxa
that may prevent the colonization of the human intestinal
tract by ETEC in American volunteers not previously ex-
posed to the pathogen. Our results suggest a candidate list
of potential probiotics that may be successful in the
prophylaxis of traveler's diarrhea.
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